

Cancer Immunotherapy Market - 2024-2033

<https://marketpublishers.com/r/C4EBA2A0C8C7EN.html>

Date: September 2025

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: C4EBA2A0C8C7EN

Abstracts

The Cancer Immunotherapy Market was valued at US\$ 137.70 billion in 2024 and is anticipated to reach US\$ 261.74 billion by 2033, at a CAGR of 0.079 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Immunotherapy Market.

This report delivers a comprehensive overview of the Cancer Immunotherapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Immunotherapy Market. The Cancer Immunotherapy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Cancer Immunotherapy Market Scope:

Major Highlights

This report delivers a comprehensive overview of the Cancer Immunotherapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Immunotherapy Market. The Cancer Immunotherapy Market size, estimates, and forecasts are provided

in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

- 3.1. Key Trends and Future Projections

4. SNIPPET BY TYPE

- 4.1. Snippet by Indication

5. SNIPPET BY REGION

6. DYNAMICS

- 6.1. Impacting Factors
 - 6.1.1. Drivers
 - 6.1.1.1. Rising Incidence and Prevalence of Cancer

7. RISING NOVEL IMMUNOTHERAPY DEVELOPMENT ACTIVITIES AND APPROVALS

8. RESTRAINTS

- 8.1. High Cost of Immunotherapies

9. PATIENT ADHERENCE AND COMPLIANCE ISSUES

10. OPPORTUNITIES

- 10.1. Rising Demand from Emerging Countries

10.1.1. Impact Analysis

11. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

11.1. Epidemiology

11.2. Market Leaders and Pioneers

11.3. Latest Developments and Breakthroughs

11.4. Pipeline Analysis

11.5. Regulatory and Reimbursement Landscape

11.6. Pricing Analysis

11.7. Porter's Five Forces Analysis

11.8. Patent Analysis

11.9. SWOT Analysis

11.10. Unmet Needs and Gaps

11.11. Recommended Strategies for Market Entry and Expansion

11.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

12. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TYPE

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

12.1.2. Market Attractiveness Index, By Type

12.2. Immune Checkpoint Inhibitors*

12.2.1. Introduction

12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

12.2.3. Pembrolizumab

12.2.4. Atezolizumab

12.2.5. Avelumab

12.2.6. Nivolumab

12.2.7. Durvalumab

12.2.8. Ipilimumab

12.2.9. Others

12.3. Cytokines

12.4. Cancer Vaccines

12.5. Adoptive Cell Therapy

12.5.1. Tumor Infiltrating Lymphocyte (TIL) Therapy

12.5.2. Engineered T-Cell Receptor (TCR) Therapy

12.5.3. Chimeric Antigen Receptor (CAR) T Cell Therapy

12.5.4. Natural Killer (NK) Cell Therapy

12.6. Other Immunotherapies

13. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY INDICATION

13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

13.1.2. Market Attractiveness Index, By Indication

13.2. Non-Small Cell Lung Cancer (NSCLC)*

13.2.1. Introduction

13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

13.3. Melanoma

13.4. Colorectal Cancer

13.5. Renal Cell Carcinoma

13.6. Breast Cancer

13.7. Bladder Cancer

13.8. Others

14. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION

14.1. Introduction

14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

14.1.2. Market Attractiveness Index, By Region

14.2. North America

14.2.1. Introduction

14.2.2. Key Region-Specific Dynamics

14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.2.5.1. U.S.

14.2.5.2. Canada

14.2.5.3. Mexico

14.3. Europe

14.3.1. Introduction

14.3.2. Key Region-Specific Dynamics

14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.3.5.1. Germany

14.3.5.2. U.K.

- 14.3.5.3. France
- 14.3.5.4. Spain
- 14.3.5.5. Italy
- 14.3.5.6. Rest of Europe
- 14.4. South America
 - 14.4.1. Introduction
 - 14.4.2. Key Region-Specific Dynamics
 - 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.4.5.1. Brazil
 - 14.4.5.2. Argentina
 - 14.4.5.3. Rest of South America
- 14.5. Asia-Pacific
 - 14.5.1. Introduction
 - 14.5.2. Key Region-Specific Dynamics
 - 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.5.5.1. China
 - 14.5.5.2. India
 - 14.5.5.3. Japan
 - 14.5.5.4. South Korea
 - 14.5.5.5. Rest of Asia-Pacific
- 14.6. Middle East and Africa
 - 14.6.1. Introduction
 - 14.6.2. Key Region-Specific Dynamics
 - 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

15. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

- 15.1. Competitive Overview and Key Market Players
- 15.2. Market Share Analysis and Positioning Matrix
- 15.3. Strategic Partnerships, Mergers & Acquisitions
- 15.4. Key Developments in Product Portfolios and Innovations
- 15.5. Company Benchmarking

16. COMPANY PROFILES

Key Market Players

1. MERCK & CO., INC.*

1.1. Company Overview

1.1.1. Product Portfolio

1.1.1.1. Product Description

1.1.1.2. Product Key Performance Indicators (KPIs)

1.1.1.3. Historic and Forecasted Product Sales

1.1.1.4. Product Sales Volume

1.1.2. Financial Overview

1.1.2.1. Company Revenue's

1.1.2.2. Geographical Revenue Shares

1.1.2.3. Revenue Forecasts

1.1.3. Key Developments

1.1.3.1. Mergers & Acquisitions

1.1.3.2. Key Product Development Activities

1.1.3.3. Regulatory Approvals, etc.

1.1.4. SWOT Analysis

1.2. Johnson & Johnson Services, Inc.

1.3. Bristol-Myers Squibb Company

1.4. AstraZeneca

1.5. Pfizer Inc.

1.6. F. Hoffmann-La Roche Ltd

1.7. Novartis AG

1.8. Kite Pharma, Inc.

1.9. Dendreon Pharmaceuticals LLC.

1.10. Amgen Inc. (*THE LIST IS NOT EXHAUSTIVE)

2. APPENDIX

2.1. About Us and Services

2.2. Contact Us

I would like to order

Product name: Cancer Immunotherapy Market - 2024-2033

Product link: <https://marketpublishers.com/r/C4EBA2A0C8C7EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4EBA2A0C8C7EN.html>